For 2QCY2017, Sanofi India posted results which were below expectations on all fronts. The sales came in at `556cr v/s. `520cr expected, registering a yoy de-growth of 3.8%. On the operating front, the EBITDA margin came in at 12.7% (17.6% expected) v/s. 18.6% in 2QCY2016. Despite better GPM (Gross Profit Margin), which came in at 55.5% v/s. 51.5% in 2QCY2016, the EBIDTA margin was lower, as the other expenses rose by 35.7% yoy, while employee expenses rose by 12.4% yoy. Consequently, the Adj. PAT came in at `74cr v/s. `86cr in 2QCY2016, a yoy de-growth of 14.4%. This was against the expectations of `82cr. We maintain our Neutral rating.
Download Full Report View Full Report in BrowserPlease Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...